Cosciens Biopharma Inc
Company Profile
Business description
Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing pharmaceutical and diagnostic products and active ingredients for the healthcare and cosmetics industries. It operates through two segments: Active Ingredient and Biopharmaceutical. The Active Ingredient segment, which generates maximum revenue, focuses on plant-based ingredients derived from oats and other renewable resources, including oat beta glucan, oat oil, and avenanthramides. The Biopharmaceutical segment focuses on the development and commercialization of therapeutics and diagnostic tests, including its product Macrilen, and advancing a pre-clinical pipeline targeting unmet medical needs, particularly in rare or orphan indications. It operates in Canada, Germany, the United States, and Austria.
Contact
C/o Borden Ladner Gervais Llp
Suite 3400, 22 Adelaide Street West
TorontoONM5H 4E3
CANT: +1 843 900-3223
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
28
Stocks News & Analysis
stocks
Jet fuel price spike weighing on Australian airline profits
stocks
US utilities stocks keep rallying as investors bet on power demand growth
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,173.60 | 36.60 | -0.40% |
| CAC 40 | 8,276.55 | 1.98 | 0.02% |
| DAX 40 | 24,162.41 | 95.71 | 0.40% |
| Dow JONES (US) | 48,505.53 | 41.81 | 0.09% |
| FTSE 100 | 10,591.16 | 31.58 | 0.30% |
| HKSE | 26,394.26 | 521.94 | 2.02% |
| NASDAQ | 24,076.63 | 60.62 | 0.25% |
| Nikkei 225 | 59,518.34 | 1,640.95 | 2.84% |
| NZX 50 Index | 13,066.06 | 48.80 | 0.37% |
| S&P 500 | 7,038.22 | 15.27 | 0.22% |
| S&P/ASX 200 | 8,955.00 | 56.40 | -0.63% |
| SSE Composite Index | 4,055.55 | 28.34 | 0.70% |